Pancreatic Cancer Research

ResearcherUniversity College HospitalActive in the last 2 years

Matthew Thomas Huggett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0612-5643; OpenAlex author ID A5048772862. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 6

  1. Editorial Note: Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Co-author DOI 10.18632/oncotarget.28902↗
  2. Utility of interventional endoscopic ultrasound in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1252824↗
  3. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Co-author DOI 10.18632/oncotarget.7611↗
  4. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2014.95↗
  5. CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Co-author DOI 10.1088/0031-9155/59/8/1911↗
  6. Diagnosing and managing pancreatic cancer. Co-author PMID 21932502↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stephen P. Pereira · 5 shared papers, 2011–2026 · strength 0.52
  2. Margaret Geraldine Keane · 2 shared papers, 2016–2026 · strength 0.38
  3. Bharat Paranandi · 1 shared paper, 2023 · strength 0.24
  4. Wei On · 1 shared paper, 2023 · strength 0.24
  5. Tayyaba Hasan · 2 shared papers, 2014 · strength 0.08
  6. Michael Jermyn · 2 shared papers, 2014 · strength 0.08
  7. Brian W. Pogue · 2 shared papers, 2014 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.